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Tumour-vasculature development via endothelial-
to-mesenchymal transition after radiotherapy
controls CD44v6+ cancer cell and macrophage
polarization
Seo-Hyun Choi1,4, A-Ram Kim1, Jae-Kyung Nam1, Jin-Mo Kim2, Jee-Youn Kim2, Haeng Ran Seo3, Hae-June Lee1,
Jaeho Cho 2 & Yoon-Jin Lee 1
It remains controversial whether targeting tumour vasculature can improve radiotherapeutic
efﬁcacy. We report that radiation-induced endothelial-to-mesenchymal transition (EndMT)
leads to tumour vasculature with abnormal SMA+NG2+ pericyte recruitment during tumour
regrowth after radiotherapy. Trp53 (but not Tgfbr2) deletion in endothelial cells (ECs)
inhibited radiation-induced EndMT, reducing tumour regrowth and metastases with a high
CD44v6+ cancer-stem-cell (CSC) content after radiotherapy. Osteopontin, an EndMT-
related angiocrine factor suppressed by EC-Trp53 deletion, stimulated proliferation in dor-
mant CD44v6+ cells in severely hypoxic regions after radiation. Radiation-induced EndMT
signiﬁcantly regulated tumour-associated macrophage (TAM) polarization. CXCR4 upregu-
lation in radioresistant tumour ECs was highly associated with SDF-1+ TAM recruitment and
M2 polarization of TAMs, which was suppressed by Trp53 deletion. These EndMT-related
phenomena were also observed in irradiated human lung cancer tissues. Our ﬁndings suggest
that targeting tumour EndMT might enhance radiotherapy efﬁcacy by inhibiting the re-
activation of dormant hypoxic CSCs and promoting anti-tumour immune responses.
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Despite recent technological advances in radiotherapy,challenges relating to tumour targeting, dose limitations,and tumour relapse and escape remain. Multiple strate-
gies for targeting cancer cells, cancer stem cells (CSCs), tumour
stroma, and tumour endothelial cells (ECs), as well as improving
anti-tumour immune responses to increase tumour radio-
sensitivity, are being developed1–3.
Anti-angiogenic or vascular-destructive agents potentially
enhance tumour responses to radiotherapy4. Several anti-
angiogenics have been clinically evaluated in combination with
radiotherapy5,6; however, their beneﬁts are controversial. Bone
marrow-derived cell (BMDC) recruitment to irradiated tumours
may contribute to tumour relapse via vasculogenesis7,8. Although
tumour-vasculature development after radiotherapy is not well
characterized, targeting tumour ECs enhances radiotherapeutic
efﬁcacy; ceramide, sphingomyelinase, and Bax regulate EC
apoptosis after irradiation9,10. Vascular damage may affect
tumour responses to high radiation doses, e.g., during stereotactic
radiosurgery/radiotherapy11,12. ECs lacking ataxia-telangiectasia
mutated showed increased radiosensitivity13. However, it remains
debatable whether EC targeting can improve radiotherapy
efﬁcacy.
Cancer cells that acquire radioresistance exhibit CSC-like
characteristics1,14. CSCs are often quiescent after radiation or
chemotherapy and their awakening causes tumour relapse and
escape15,16. Understanding the mechanism regulating the dor-
mant or proliferative status better is important for targeting
CSCs.
Radiotherapy can stimulate anti-tumour immune responses.
Immunomodulation using antibodies against programmed death
1 and programmed death-ligand 1 in combination with radio-
therapy has been assessed in clinical trials17. Radiotherapy can
enhance immunosuppressive responses, including chemotactic
signals that recruit several myeloid cell types17. Radio-
immunomodulation studies have revealed crucial strategies for
effectively combining immunotherapy and radiotherapy.
Endothelial-to-mesenchymal transition (EndMT) promotes
cancer-associated ﬁbroblast formation in tumours18, affects the
endothelium to enable tumour-cell extravasation19, and may give
rise to pericyte-like cells within tumours20. Pericytes play critical
roles in blood-vessel maturation and blood-barrier maintenance
and regulate vessel integrity and function by interacting with
ECs21,22. Tumour vessels harbouring less pericytes are more
sensitive to radiation and chemotherapy20,23.
Here, we studied tumour EndMT and pericyte-derived tumour
vasculature during tumour regrowth after radiotherapy. We
analysed the effects of EndMT-regulated vasculature on the
irradiated tumour microenvironment, especially, hypoxic dor-
mant CSCs and tumour-associated macrophage (TAM) polar-
ization of bone marrow-derived monocytes (BMDMs).
Results
Trp53 and Tgfbr2 conversely regulate EndMT in vitro. We
previously reported radiation-induced EndMT in several EC
types24–26. Trp53 is a key regulator of radiation responses in ECs,
and tansforming growth factor-β (TGFβ)-related signalling
potentially is a key regulator of EndMT27,28. Thus, we explored
the effects of small interfering RNA (siRNA)-mediated knock-
down of Trp53 and Tgfbr2 on radiation-induced EndMT in
human umbilical vein ECs (HUVECs). At 48 h post irradiation
(hpi), Trp53 silencing in HUVECs markedly inhibited
irradiation-induced messenger RNA (mRNA) expression of
Snail1, Snail2, and Zeb2, which encode transcription factors
implicated in EndMT29, compared to control siRNA-treated cells,
whereas Tgfbr2 knockdown increased their expression
(Supplementary Fig. 1a, b). Accordingly, overexpression of Trp53,
but not Tgfbr2, augmented irradiation-induced increases in the
EndMT markers ﬁlamentous actin, vimentin, and smooth muscle
actin (SMA), while reversing irradiation inhibited CD31 levels
(Supplementary Fig. 1c, d). Pericytes signiﬁcantly restored
irradiation-induced tubule formation impairment, but not upon
Trp53 knockdown, which inhibited pericyte recruitment (Sup-
plementary Fig. 1e). In contrast, Tgfbr2 knockdown signiﬁcantly
enhanced pericyte integration into irradiated EC complexes and
recovered EC tubule formation (Supplementary Fig. 1e).
EC-Trp53 KO inhibits EndMT-related abnormal vasculature.
Inspired by our ﬁndings in vitro, we next analysed tumour-
vasculature development during regression and regrowth after
radiotherapy in syngeneic mouse tumours of colon carcinoma
cells (CT26). The changes in tumour size are shown in Supple-
mentary Fig. 2a. Irradiation signiﬁcantly increased collagen
deposition, especially around tumour vessels, during regression
and regrowth, and CD31+ areas (indicative of EC) and vessels
were more dilated than in non-irradiated tumours (Supplemen-
tary Fig. 2b, c). The SMA+CD31+ population was signiﬁcantly
increased around hypoxic regions and was labelled with pimo-
nidazole during tumour regression and regrowth (Supplementary
Fig. 2d, e).
To study the potential relationship between tumour vascula-
ture and radioresistance, we used EC-speciﬁc Trp53-knockdown
(EC-p53KD) and -knockout (EC-p53KO) mice (Tie2-Cre;
Trp53ﬂox/+ and Tie2-Cre;Trp53ﬂox/ﬂox, respectively). A syngeneic
tumour model was established by implanting tumour cells
(referred to as KP cells) isolated from a spontaneous lung
adenocarcinoma in conditional KrasG12D;Trp53ﬂox/ﬂox mice30.
Primary KP cells were implanted at passage 4 or less to maintain
the cellular characteristics of spontaneous lung tumour. Trp53
mRNA–VE-cadherin+ cells were dominant in EC-p53KO, but
not wild-type (WT) tumours, indicating that p53 was successfully
knocked out in tumour ECs of EC-p53KO mice (Supplementary
Fig. 3a).
KP tumours in WT, EC-p53KD, and EC-p53KO mice reached
150 mm3 within comparable periods (Fig. 1a). However, follow-
ing 20 Gy irradiation, tumour growth was signiﬁcantly delayed in
EC-p53KD/KO compared with WT mice (Fig. 1b, c). At 7 days
post irradiation (dpi), necrotic areas and the apoptotic cell
population were increased more in p53KO than in WT tumours
(Fig. 1d, Supplementary Fig. 3b). Immunoﬂuorescence analyses
revealed that SMA+CD31+ lesions were signiﬁcantly larger in
peri- and intratumoural regions in irradiated (day 23) than in
non-irradiated WT (day 15), but not EC-p53KO mice (Fig. 1e).
CD31 and SMA colocalized (indicating EndMT) in WT, but not
EC-p53KO ECs, on 3 and 23 dpi (Fig. 1f, Supplementary Fig. 3c).
CD31+ areas and vessel diameters were prominently larger
during tumour regrowth post irradiation than in non-irradiated
tumours (Supplementary Fig. 3d). SMA was highly expressed post
irradiation in most tumour cells (besides ECs) in WT, whereas
this was less evident in EC-p53KO mice (Fig. 1f, Supplementary
Fig. 3e). Concurrently with increased SMA expression, collagen
deposition increased signiﬁcantly after irradiation in WT, but not
EC-p53KD/KO mice (Supplementary Fig. 3f).
Many WT tumour vessels were covered with SMA+NG2+
pericytes 23 dpi compared with non-irradiated tumours in WT,
but not EC-p53KO mice (Fig. 1g, h). Vessels with SMA+NG2+
pericytes appeared at 3 dpi, and most NG2+ pericytes colocalized
with SMA in irradiated WT tumour vessels (Supplementary
Fig. 4a), concomitantly with radiation-induced EndMT. Desmin,
another pericyte marker31, was detected in irradiated WT
tumours but did not colocalize with NG2+ cells (Supplementary
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Fig. 4b). We analysed the EndMT and pericyte population in
greater detail by endothelial lineage tracking using cells expres-
sing tdTomato-labelled Cre. To this end, we generated EC-
tdTomato and EC-tdTomato;p53KO mice (Tie2-Cre;tdTomato
and Tie2-Cre;tdTomato Trp53ﬂox/ﬂox, respectively)
(Supplementary Fig. 4c, left panel). tdTomato+SMA+ cells were
signiﬁcantly increased (>50%) at 7 dpi in tumours of EC-
tdTomato, but not EC-tdTomato-p53KO mice (Supplementary
Fig. 4c, middle-top and right panel). However, tdTomato+NG2+
cells were not detected in EC-tdTomato mice (Supplementary
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Fig. 4c, middle-bottom panel). During post-irradiation tumour
regrowth, SMA+ mesenchymal cell or NG2+SMA+ pericyte
populations signiﬁcantly increased around irradiated vessels.
Based on these data, we cautiously suggest that NG2+SMA+ cells
do not originate from ECs, whereas SMA+mesenchymal cells can
be derived from ECs via EndMT.
EndMT (SMA+CD31+) cells in WT tumours were less
TUNEL– or γH2AX– at 3 dpi, but highly Ki67+ (indicative of
cell proliferation) during tumour regrowth (23 dpi), in contrast to
SMA− ECs in EC-p53KO mice (Fig. 1i and Supplementary
Fig. 4d, e). To evaluate whether irradiated tumour EndMT vessels
were functional, mice were intravenously injected with Hoechst
33342. Hoechst 33342 accumulated signiﬁcantly more around
EndMT-associated vessels in WT than in EC-p53KO tumours
upon irradiation (Supplementary Fig. 4f). Further, signiﬁcant
ﬂuorescein isothiocyanate–dextran leakage (indicative of intratu-
moural leakage) was observed in irradiated EC-p53KO compared
to irradiated WT tumours (Supplementary Fig. 4g).
EC-Tgfbr2 knockdown accelerates EndMT and tumour growth.
TGFβ signalling is important in tumour responses to
radiotherapy32,33 and regulates EndMT28. After irradiation or
TGFβ1 treatment, p-SMAD2/3 levels did not decrease in
TGFβR1-depleted HUVECs, but they did increase upon TGFβR2
depletion (Supplementary Fig. 5a, b). Radiation- or TGFβ1-
induced increases in EndMT markers (ﬁlamentous actin and
FSP1) were decreased in TGFβR1-depleted HUVECs, but were
increased in TGFβR2-depleted cells (Supplementary Fig. 5c, d).
Therefore, we studied the relationship between radiation-induced
tumour EndMT and tumour-irradiation responses in EC-speciﬁc
Tgfbr2-knockdown (EC-TGFβR2KD) mice (Tie2-Cre;Tgfbr2ﬂox/+).
Supplementary Figure 5e shows a non-irradiated tumour with
EC-speciﬁc Tgfbr2 knockdown. Post-irradiation p-SMAD2/3
levels of CD31+ vessels were signiﬁcantly higher in EC-
TGFβR2KD than in WT mice (Supplementary Fig. 5f). In syn-
geneic KP tumours, Tgfbr2 knockdown did not affect non-
irradiated tumour growth (Fig. 2a), but it signiﬁcantly enhanced
tumour growth (Fig. 2b, c) and radiation-induced EndMT
(Fig. 2d) post irradiation. Concurrently, Tgfbr2 knockdown sig-
niﬁcantly increased collagen deposition in irradiated vs. non-
irradiated tumours (Supplementary Fig. 5g). CD31 and SMA
colocalized from 1 dpi in EC-TGFβR2KD mice (Supplementary
Fig. 5h). Consistently, CD31+ tumour vessel areas with NG2+
pericytes were signiﬁcantly larger in EC-TGFβR2KD than in WT
mice (Fig. 2e). We examined γH2AX+ and TUNEL+ ECs shortly
after irradiation to evaluate early vessel responses. SMA+ vessels
were more TUNEL+ in WT than in EC-TGFβR2KD tumours at 3
dpi, but no difference in γH2AX was evident (Supplementary
Fig. 5i, j). The different tumour growth rates and pericyte
populations in WT tumours in Fig. 2b–e vs. Fig. 1b–h may reﬂect
different proliferation rates in KP cells at 10 dpi (Supplementary
Fig. 5k); after irradiation, the proliferation rate of the primary KP
cells used in the tumour-growth experiment shown in Fig. 2b was
lower than that of the KP cells represented in Fig. 1b (Supple-
mentary Fig. 5k).
EC-Trp53 KO overcomes Tgfbr2-deleted radioresistance. To
test whether Trp53-knockdown or -knockout could overcome the
increased radioresistance of EC-TGFβR2KD tumours, we gener-
ated EC-p53KD;TGFβR2KD and EC-p53KO;TGFβR2KD mice.
These mice grew to adulthood normally, and KP tumour growth
to 150 mm3 was unaffected (Fig. 2f). Following 20 Gy irradiation,
tumour growth was signiﬁcantly delayed in EC-p53KD/KO;
TGFβR2KD vs. EC-TGFβR2KD mice (Fig. 2g, h). Vessel numbers
with SMA+NG2+ pericytes decreased markedly after irradiation
in EC-p53KO;TGFβR2KD vs. EC-TGFβR2KD tumours, but
increased in TGFβR2KD vs. WT tumours (Fig. 2i).
Increasing evidence implicates BMDCs in vessel formation,
especially vasculogenesis, in irradiated tumours7. To examine the
relationship between BMDCs and tumour EndMT, we analysed
tumour regrowth following radiotherapy in CT26 tumour-
bearing mice after transplantation of CM-Dil (cell tracker)-
labelled BMDCs (Fig. 2j). BMDCs did not colocalize with CD31+
cells during tumour regrowth, but showed a pericyte-like
phenotype around ECs (Fig. 2j). Tumour vessels in WT and
EC-p53KO mice that had received BMDCs from Tie2-GFP mice
did not colocalize with GFP+ cells (endothelial progenitor cells)
during tumour regrowth after radiotherapy (Fig. 2k). Indeed,
vessels around recurrent lung tumours did not show EndMT
(Supplementary Fig. 6).
EC-Trp53 KO affects hypoxic CD44v6+ cell proliferation. In
radioresistant CSCs during tumour regrowth, aldehyde dehy-
drogenase+, CD44+, CD133+, and epithelial adhesion molecule+
lesion areas increased by 11%, 19%, 24%, and 4% respectively, in
irradiated vs. control tumours, which showed no signiﬁcant differ-
ence compared to irradiated EC-p53KO tumours (Supplementary
Fig. 7a, b). However, CD44v6+ areas increased by >50% in WT
tumours but remained at 29% in EC-p53KO tumours after radio-
therapy (Fig. 3a, Supplementary Fig. 7a). The CD44v6+ cell popu-
lation was the most strongly increased after radiotherapy. We
hypothesize that CD44v6 may be the only tested CSC marker
affected by radiation-induced tumour EndMT. Using green ﬂuor-
escent protein (GFP)-overexpressing CT26 cells, we veriﬁed that
mainly CD44v6 was increased in GFP+ cell membranes during
tumour regression and regrowth when compared to non-irradiated
Fig. 1 EC-Trp53 deletion inhibits EndMT, vascular abnormality, and KP tumour regrowth after irradiation. KP lung tumour cells were subcutaneously
injected into the right hind legs of WT, Tie2-Cre;Trp53ﬂox/+(EC-p53KD), and Tie2-Cre;Trp53ﬂox/ﬂox (EC-p53KO) mice. Tumour tissues (150–200mm3)
were obtained from non-irradiated animals (days 0, 15) and after 20 Gy irradiation (IR; days 3, 23). Unless otherwise indicated, the numbers of animals in
the respective groups were as follows: WT, n= 8; EC-p53KD, n= 7; EC-p53KO, n= 7; WT mice+IR, n= 11; EC-p53KD+IR, n= 10; EC-p53KO+IR, n= 10. a
Days required for tumours to reach 150mm3 (WT, n= 19; EC-p53KD, n= 17; EC-p53KO, n= 17). b Tumour growth with or without irradiation. c Tumour
sizes on days 15 (no irradiation) and 23 (after irradiation). d Quantiﬁcation of the necrotic area per ﬁeld (magniﬁcation, ×100) using H&E-stained images of
tumours from WT and EC-p53KO mice, with or without irradiation (3 and 7 dpi). e, f Immunoﬂuorescence of CD31 and αSMA in tumours on 0 and 23 dpi
(e; Scale bar= 50 μm, f; Scale bar= 10 μm (crop, 5 μm)). Quantiﬁcation of the αSMA+CD31+/CD31+ area as an average of 5 ﬁelds (magniﬁcation, ×100)
in (d) (no IR, n= 7; IR, n= 10). g, h Immunoﬂuorescence of CD31, αSMA, and NG2 in tumours, with or without irradiation (23 dpi) and three-dimensional
(3D) image reconstruction (g). Quantiﬁcation of CD31+ with NG2+ pericyte coverage in the total CD31+ area and αSMA+NG2+ cells in the total NG2+
area (magniﬁcation, ×100; n≥ 5) from (h). Immunoﬂuorescence of CD31, αSMA, and Ki67 in tumours from WT and EC-p53KO at 23 dpi. i The percentage
of αSMA+CD31+Ki67+ and αSMA–CD31+Ki67+ vessels among all CD31+ vessels per ﬁeld (magniﬁcation, ×100; n≥ 5). Scale bar= 20 μm (crop, 10 μm).
For (a–c), error bars indicate SD. For (e–i), error bars indicate SEM; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, ns not signiﬁcant (one-way
ANOVA for multiple comparison). Data are representative of three independent experiments
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tumours (Supplementary Fig. 7c). Next, we studied whether this
CD44v6+ population increase resulted from CD44v6– primary KP
cells that became CD44v6+ after irradiation or was derived from
proliferating radioresistant CD44v6+ cells. CD44v6+ cell numbers
signiﬁcantly increased at 3 and 7 dpi in WT, but not EC-p53KO
tumours (Supplementary Fig. 7d). CD44v6+ cells in WT tumours
were TUNEL– at 3 dpi, and the TUNEL+-to-total tumour area ratio
was only 2.3% (Supplementary Fig. 7d). Indeed, in primary KP cells,
the CD44v6+ population increased in a dose-dependent manner at
24 hpi (Supplementary Fig. 7e).
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During tumour regrowth after 20 Gy irradiation, the
pimonidazole-positive hypoxic area and staining intensity
increased more in EC-p53KO than in WT tumours (Fig. 3b).
However, in non-irradiated tumours, hypoxia was comparable
between EC-p53KO and WT tumours (Fig. 3b, upper graphs).
We hypothesize that EndMT inhibition in irradiated EC-p53KO
tumours resulted in a loss of pericyte coverage and subsequent
vascular leakage, resulting in increased tumour hypoxia.
CD44v6+ tumour cells localized independently of the hypoxic
region. Notably, CD44v6+ cancer cells that localized in radiation-
induced, extremely hypoxic regions of EC-p53KO tumours were
Ki67– (no proliferation), in contrast to CD44v6+ cancer cells in
non-severely hypoxic areas of irradiated WT tumours (Fig. 3b,
lower left graph). The number of Ki67+ cells per tumour section
was remarkably lower in EC-p53KO than in WT tumours,
following radiotherapy (Fig. 3b, lower right graph). We
hypothesize that several days after irradiation, vascular disruption
in EC-p53KO tumours signiﬁcantly increases, with subsequent
formation of functionally defective vessels. Thus, severely hypoxic
regions observed in EC-p53KO tumours may limit CD44v6+ cell
proliferation during tumour regrowth. Surprisingly, the number
of KP metastatic nodules in the lungs was signiﬁcantly lower in
EC-p53KO than in WT mice after irradiation (Fig. 3c–e).
Notably, in irradiated WT mice, >60% of cells in metastatic
(KrasG12D) lung tumour colonies (>100 μm tumour diameter)
were CD44v6+ vs. 25% in non-irradiated mice (Fig. 3e).
EC-Tgfbr2 knockdown did not affect tumour hypoxia and
CD44v6+ cell proliferation in hypoxic regions after radiotherapy
(Fig. 3f). Consistently, CD44v6+ tumour cell numbers signiﬁ-
cantly more strongly increased 24 dpi in EC-TGFβR2KD vs. WT
mice (Fig. 3f). The number of lung-metastatic tumour colonies
was signiﬁcantly increased in EC-TGFβR2KD vs. WT mice after
irradiation, and CD44v6+ cells were more prominent in
irradiated than in non-irradiated metastatic tumours (Fig. 3g,
Supplementary Fig. 8a). In agreement herewith, KP lung-
metastatic nodule numbers were signiﬁcantly decreased in EC-
p53KD/KO;TGFβR2KD vs. WT mice after radiotherapy (Fig. 3h).
Lung-metastatic tumour cells did not originate from NG2+SMA+
pericytes in irradiated tumours, indicating the important role of
radiation-induced CD44v6+ cells in metastasis (Supplementary
Fig. 8b).
EC-Trp53 KO does not reduce tumour growth after fractio-
nated radiotherapy. To examine whether fractionated radio-
therapy inﬂuences EndMT, we irradiated WT and EC-p53KO
tumours with 30 Gy in six fractions (Supplementary Fig. 9a). We
observed no difference in tumour growth and lung metastasis
between WT and EC-p53KO (Supplementary Fig. 9b-d).
However, the fractionated irradiation-induced increase in the
SMA+CD31+ population in WT tumours was signiﬁcantly
inhibited in EC-p53KO tumours, whereas pimonidazole-staining
intensity and the Ki67+CD44v6+ cancer cell population in
hypoxic areas were not different between WT and EC-p53KO
tumours (Supplementary Fig. 9e, f).
In addition, we examined the effect of 20 Gy exposure in daily
2 Gy fractions in WT tumours and EC-p53KO mice established
by systemic tamoxifen-mediated-speciﬁc Cre recombination in
the VE-cadherin promoter (Supplementary Fig. 9g-k). After daily
2 Gy fractions, WT tumour growth was signiﬁcantly higher than
that observed with a single 20 Gy dose. However, EndMT
occurrence and hypoxic staining density in WT tumours was
signiﬁcantly decreased after fractionated compared to a single
high-dose irradiation (Supplementary Fig. 9j, k). Coincident with
WT tumour growth, the proliferative CD44v6+ cancer cell
population in hypoxic areas increased more with 2 Gy fractions
than with the 20 Gy dose (Supplementary Fig. 9k). Moreover, no
difference in tumour growth and the Ki67+CD44v6+ population
occurred in the hypoxic areas in WT and EC-p53KO mice after
10 daily 2 Gy fractions, even though EC-p53KO signiﬁcantly
reduced EndMT.
EndMT-related Osteopontin stimulates dormant CD44v6+
cells. To elucidate whether TRP53 is critical for radiation-
induced EndMT, we subjected HUVECs transfected with siRNAs
against Trp53, Tgfbr2, or Trp53+Tgfbr2 mRNA to RNA-
sequencing (RNA-seq) analysis. Various EndMT progression-
associated molecules were upregulated at 48 hpi (Fig. 4a). In
TGFβR2-silenced ECs, these patterns were more pronounced,
whereas in Trp53-deﬁcient cells, the expression of genes pro-
moting EndMT progression was signiﬁcantly decreased, and
TGFβR2-enhanced EndMT-related genes were downregulated
(Fig. 4a). Quantitative reverse-transcription PCR (RT-qPCR)
data indicated that EC-speciﬁc gene expression was not sig-
niﬁcantly changed, whereas expression of ﬁbroblast-associated
genes, including ﬁbroblast-activation protein (FAP) and alpha
smooth muscle actin (ACTA2), prominently increased during
radiation-induced EndMT, indicating that TRP53 is a key reg-
ulator of radiation-induced EndMT (Fig. 4b). Moreover, irra-
diation downregulated EC-speciﬁc genes (CD34, PECAM-1,
CDH5, and KDR) and upregulated ﬁbroblast-speciﬁc genes
(COL1A1, COL6A1, ACTA2, FN1, and FAP) in KP ECs isolated
from WT, but not EC-p53KO mice (Supplementary Fig. 10a, b).
In addition, OPN mRNA levels increased by >7-fold in control
and TGFβR2-deﬁcient ECs at 48 hpi, but were signiﬁcantly
suppressed by Trp53 knockdown (Fig. 4c). Coincident with
OPN upregulation, secreted OPN increased in control and
Fig. 2 EC-Trp53;Tgfbr2 dual silencing overcomes tumour radioresistance associated with EC-Tgfbr2 knockdown. a–e KP cells were injected subcutaneously
into the right hind legs of WT and Tie2-Cre;Tgfbr2ﬂox/+ (EC-TGFβR2KD) mice. Tumour tissues were obtained before and 24 dpi (WT mice, n= 12; EC-
TGFβR2KD mice, n= 14). a Days required for tumours to reach 150mm3 after KP cell injection. b Tumour growth following a single 20 Gy irradiation dose.
c Tumour size at 24 dpi. d Immunoﬂuorescence of CD31 and αSMA in tumours 24 dpi, with αSMA+CD31+ cell quantiﬁcation (magniﬁcation, ×200; n > 5).
Scale bar= 20 μm (crop, 5 μm). e Immunoﬂuorescence of CD31, αSMA, and NG2 in irradiated tumours (24 dpi) and quantiﬁcation of vessels with NG2+
pericytes (magniﬁcation, ×200; n > 5). Scale bar= 50 μm (crop, 5 μm). f–i KP cells were injected subcutaneously into the right hind legs of WT, Tie2-Cre;
Trp53ﬂox/+Tgfbr2ﬂox/+ (EC-p53KD;TGFβR2KD), and Tie2-Cre;Trp53ﬂox/ﬂoxTgfbr2ﬂox/+ (EC-p53KO;TGFβR2KD) mice. Tumour tissues were obtained before
and 28 dpi (WT mice, n= 7; EC-TGFβR2KD mice, n= 6; EC-p53KD;TGFβR2KD mice, n= 6; EC-p53KO;TGFβR2KD mice, n= 6). f Days required for
tumours to reach 150mm3 after KP cell injection. g Tumour growth after 20 Gy irradiation in a single dose. h Tumour size on 28 dpi. i Immunoﬂuorescence
of CD31, αSMA, and NG2 in KP tumours 28 dpi, and αSMA+CD31+ vessels with NG2+ pericytes quantiﬁcation (magniﬁcation, ×200; n > 5). j
Immunoﬂuorescence of CM-Dil and CD31 in CT26 tumours from WT mice. WT mice were locally irradiated (Local IR), whole-body irradiated (WBI), or
WBI and transplanted with WT mouse-derived BM (labelled with CM-Dil). Scale bar= 50 μm (crop, 10 μm). k GFP and CD31 in tumours fromWT and EC-
p53KO mice 28 dpi. WT or EC-p53KO mice were WBI and transplanted with Tie-2;GFP mouse-derived BM cells. Scale bar= 20 μm. The error bars indicate
SD (a–c, f–h) or SEM (d, e, i); *p < 0.05, **p < 0.01, ****p < 0.0001, ns not signiﬁcant (a–c: Student’s t-test, f–h: one-way ANOVA for multiple comparison).
All data are representative of three independent experiments
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TGFβR2-deﬁcient ECs at 5 dpi, but signiﬁcantly decreased after
Trp53 knockdown in conditioned HUVEC medium (Supple-
mentary Fig. 10c). Cytokine immunoassays with conditioned
media conﬁrmed that irradiated ECs secreted more OPN than
did non-irradiated ECs (Fig. 4d).
Because OPN can interact with CD4434, we analysed the
relation between EC-secreted OPN and CD44v6+ CSCs in
irradiated tumours. Surprisingly, SMA+ tumour ECs of irradiated
WT, but not EC-p53KO mice highly expressed OPN (Fig. 4e,
Supplementary Fig. 11a). Signiﬁcant OPN secretion from vessels
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that underwent EndMT occurred 7 dpi (Supplementary Fig. 11b).
Notably, CD44v6+ CSCs preferentially localized adjacent to OPN+
ECs in irradiated WT tumours, but not in non-irradiated WT and
irradiated EC-p53KO tumours (Fig. 4f, g).
In contrast, EC-Tgfbr2 knockdown increased OPN+CD44v6+
regions after radiotherapy (Supplementary Fig. 11c). To investi-
gate the effects of OPN on dormant CD44v6+ CSCs in severely
hypoxic regions, we analysed the proliferative portion of
irradiated CD44v6+ CSCs under normoxic (20% O2) and hypoxic
(1%/0.5% O2) conditions with/without OPN, in vitro. Hypoxia
increased CD44v6 expression, with non-proliferative (Ki67–) KP
cells surviving after irradiation (Fig. 4h). Fluorescence-activated
cell sorting (FACS) analysis conﬁrmed that under hypoxia,
irradiated KP cells in the EdU+ population showed signiﬁcantly
increased CD44v6 expression in the presence of OPN (Fig. 4i).
Moreover, immunoﬂuorescence data showed that nuclear expres-
sion of several stemness markers (Oct-4/Sox-2/β-catenin)
increased substantially in the OPN-induced CD44v6+ population
under hypoxia, compared to irradiated KP cells (Supplementary
Fig. 11d).
To delineate the role of OPN secretion during post-
radiotherapy tumour regrowth, we examined the effects of a
neutralizing anti-OPN antibody on EC-TGFβR2KD tumours.
Notably, in EC-TGFβR2KD mice, the anti-OPN antibody
reduced tumour growth after irradiation, compared to control
IgG (Supplementary Fig. 12a). However, compared to control
IgG, the anti-OPN antibody markedly reduced the formation of
OPN+SMA+ vessels (from >60 to 10%) and proliferative CD44v6+
cells in EC-TGFβR2KD tumours at 21 dpi, and it induced similar
effects in WT tumours (Supplementary Fig. 12b, c).
EndMT modulates M1/M2 TAM populations after radio-
therapy. RNA-seq analysis was used to investigate the effects of
TRP53-regulated EndMT on the tumour environment during
post-irradiation tumour growth. Among genes coregulated in
irradiated cells with/without TGFβR2 siRNA (indicated by an
asterisk in Fig. 5a, left), genes adversely regulated by Trp53
knockdown were considered for further analysis. Network ana-
lysis of matrisome- and surface-associated genes (Fig. 5a, right)
indicated that enrichment for leukocyte migration- and extra-
cellular organization-related genes strongly correlated with
TRP53-regulated, radiation-induced EndMT (Fig. 5b).
Because radiation causes leukocyte recruitment, which likely
regulates tumour responses to radiotherapy35, we examined TAM
patterns after radiotherapy. At 7 dpi, arginase 1 (Arg1)+F4/80+
TAMs (M2-type) were highly accumulated in irradiated WT, but
not EC-p53KO tumour vessels, compared to non-irradiated
control vessels (Fig. 5c, left). Radiation signiﬁcantly increased the
population of iNOS+F4/80+ TAMs (M1-type) in WT tumours
(Fig. 5c, right). The M1-type TAM population was two-fold
higher in EC-p53KO than in WT tumours after radiation (Fig. 5c,
d, upper panels). In contrast, radiation induced a stronger
increase in M2-type TAMs in EC-TGFβR2KD than in WT
tumours, whereas M1-type TAMs were lower in EC-TGFβR2KD
than in WT tumours after radiation (Fig. 5d, lower panels and
Supplementary Fig. 13a). FACS analysis conﬁrmed that radiation
increased the proportion of the F4/80+CD206+ M2 to total
TAMs by >2-fold in WT, but not EC-p53KO tumours vs. non-
irradiated tumours in vivo (Fig. 5e).
To clarify whether radiation-induced tumour EndMT can
directly affect M1/M2 populations, we cocultured non-irradiated
or irradiated tumour ECs with macrophages differentiated from
BMDMs by using macrophage colony-stimulating factor (M-
CSF). When cocultured with irradiated WT, but not EC-p53KO
tumour ECs showing EndMT, F4/80+ macrophages showed an
~50% increase in the CD206+ (or Arg1+) M2 subtype vs.
macrophages cocultured with non-irradiated tumour ECs
(Fig. 5f). In contrast, the iNOS+ M1 population increased by
>50% after coculture with irradiated p53KO, but not WT tumour
ECs (Fig. 5f). Coculture with WT, but not EC-p53KO irradiated
tumour ECs, increased F4/80+ macrophage proliferation by >2.5-
fold (Fig. 5f).
EC-Trp53 KO attenuates M2 polarization of SDF-1+ TAMs.
The above RNA-seq analysis indicated that CXCR4 (SDF-1
receptor) is highly expressed on irradiated ECs, which is inhibited
by Trp53 deﬁciency (Fig. 6a). Indeed, at 7 dpi, WT tumour ECs
showed strongly increased CXCR4 expression compared to non-
irradiated tumour ECs, whereas EC-p53KO tumours did not
(Fig. 6b). Interestingly, at 1 dpi, SDF-1+ cells were highly
recruited to both irradiated WT and EC-p53KO tumours
(Fig. 6c). SDF-1+ cells often contacted tumour ECs, especially in
irradiated WT tumours (Fig. 6d). Because blood monocytes
secrete SDF-1, which promotes their differentiation into macro-
phages36, we investigated the effects of monocytic SDF-1
recruitment and endothelial CXCR4 on radiotherapy outcome.
At 7 dpi, >60% of SDF-1+F4/80+ cells appeared to be CD206+
M2 macrophages in WT, but not EC-p53KO tumours, whereas
more iNOS+ M1 macrophages were found in EC-p53KO than in
WT tumours (Fig. 6e, Supplementary Fig. 13b). These M2 sub-
type patterns were conﬁrmed by FACS analysis, which showed
that most CD206+F4/80+ cells were SDF-1+ (Fig. 6f).
Fig. 3 Elevated proliferating CD44v6+ cancer cells and lung metastasis after radiation are oppositely regulated by EC-Trp53 and EC-Tgfbr2. a
Immunohistochemistry of CD44v6+ cells in KP tumours from WT and EC-p53KO mice, with or without irradiation (23 dpi). scale bars, 100 µm.
Quantiﬁcation of the CD44v6+ area/ﬁeld (magniﬁcation, ×200). b Immunoﬂuorescence of pimonidazole, Ki67, and CD44v6 in WT and EC-p53KO
tumours 23 dpi. Scale bar= 50 μm (crop, 20 μm). Quantiﬁcation of pimonidazole-positive areas, relative pimonidazole densities, Ki67+CD44v6+ cells in
total hypoxic regions, and percentages of Ki67+ cells/ﬁeld (magniﬁcation, ×200) in (b). For all measurements, n > 5. c Quantiﬁcation of lung-metastatic
nodules/mouse from KP tumour-bearing mice at 23 dpi (n= 10). d H&E-stained lung sections (scale bars, 100 µm) from KP tumour-bearing mice 23 dpi. e
Immunoﬂuorescence of CD44v6+ and active KRAS (KRASG12D) in metastatic lung KP tumours with or without irradiation, and quantiﬁcation of the
CD44v6+ area percentage in KRASG12D+ lung-metastatic tumours (magniﬁcation, ×200; n= 10). Scale bar= 50 μm (crop, 10 μm). f Immunoﬂuorescence
of pimonidazole, Ki67, and CD44v6 in KP tumours from irradiated WT and EC-TGFβR2KD mice (24 dpi); the percent hypoxic area/ﬁeld; and the number of
Ki67+CD44v6+ cells/ hypoxic region (magniﬁcation, ×200, n > 5). Scale bar= 50 μm (crop, 20 μm). g Immunoﬂuorescence of CD44v6 and KRASG12D in
lung-metastatic KP tumours 24 dpi, and the numbers of lung-metastatic nodules/mouse (WT mice, n= 12; EC-TGFβR2KD mice, n= 14). H&E-stained lung
sections; scale bars, 100 µm, Quantiﬁcation of the CD44v6+ area/KRASG12D+ lung-metastatic tumour (magniﬁcation, ×200; n > 5). Scale bar= 50 μm
(crop, 10 μm). h Quantiﬁcation of lung-metastatic nodules/mouse from KP tumour-bearing WT (n= 7), EC-p53KD;TGFβR2KD (n= 6), and EC-p53KO;
TGFβR2KD (n= 6) mice at 28 dpi. IR irradiation (20 Gy). For (a, b, e–g), error bars indicate SEM. For (c, h) error bars indicate SD; *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001, ns not signiﬁcant (b lower, f right and g left graphs: Student’s t-test, others: one-way ANOVA). All data are representative of
three independent experiments
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To ascertain whether TRP53-regulated tumour EndMT directly
affects SDF-1+ monocyte differentiation to M1/M2 TAMs,
irradiated tumour ECs were cocultured for 48 h with macro-
phages differentiated from BMDMs by M-CSF. In accordance
with the in vivo results, most F4/80+SDF-1+ cells were CD206+
(M2) after coculture with WT tumour ECs, but iNOS+ (M1) after
coculture with EC-p53KO tumour ECs (Fig. 6g). Following
coculture with WT tumour ECs, most CD206+SDF-1+F4/80+
cells were elongated (like M2 macrophages) when differentiated
with cytokines interleukin-4 (IL-4) and IL-10 from M-CSF-
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treated BMDMs, whereas after coculture with EC-p53KO tumour
ECs, iNOS+SDF-1+F4/80+ cells were ﬂattened (like M1 macro-
phages) when differentiated with lipopolysaccharides (LPS) plus
interferon-γ (IFN- γ) from M-CSF-treated BMDMs (Fig. 6g).
We hypothesized that SDF-1+ BMDMs are preferentially
recruited by CXCR4-expressing ECs after radiotherapy. In vivo,
treatment with the CXCR4 antagonist AMD3100 signiﬁcantly
reduced SDF-1+CD206+ macrophage accumulation around
tumour vessels after radiotherapy, with increased iNOS+ M1
macrophage and non-differentiated SDF-1+ monocyte popula-
tions (Fig. 6h and Supplementary Fig. 13c). AMD3100 treatment
did not affect CXCR4 upregulation after radiation (Supplemen-
tary Fig. 13d). Radiation increased the proliferation (BrdU+) of
SDF-1+F4/80+ cells, which was inhibited by AMD3100 (Fig. 6h).
Next, we explored the responses of other immune cells in WT
and EC-p53KO tumours after radiotherapy. Immunoﬂuorescence
data showed that at 7 dpi, the population of granzyme B
(GZMB)+CD8+ cytotoxic T cells was increased in EC-p53KO,
but not WT tumours, compared to non-irradiated tumours. The
GZMB+CD8+ population was signiﬁcantly increased in irradiated
EC-p53KO tumours (Supplementary Fig. 14a). The population of
CD4+Foxp3+ regulatory T cells increased in WT tumours after
radiation, and no difference was found between irradiated WT
and EC-p53KO tumours (Supplementary Fig. 14b). Additionally,
at 7 dpi, the MHCII+ antigen-presenting cell population was
signiﬁcantly increased in EC-p53KO, but not WT tumours,
compared to non-irradiated tumours (Supplementary Fig. 14c).
EndMT-related vasculature in irradiated human lung cancer.
To evaluate the clinical relevance of our ﬁndings, we investigated
whether tumour EndMT-related vasculature appears with popu-
lations of CD44v6+ CSCs and M2 macrophages in lung tissues of
patients with lung cancer who received radiotherapy (Supple-
mentary Table 1). Because lung cancer patients who undergo
neoadjuvant concurrent chemoradiotherapy followed by surgical
resection are rare, we obtained human lung tissues after radio-
therapy (n= 10), which were compared to non-irradiated human
lung tissues (n= 10) (Supplementary Table 1). No comparable
factors were found among other clinicopathologic characteristics
(Supplementary Table 2). The patients who received radiotherapy
received fractioned doses, not a single high dose, and our mouse
studies (Supplementary Fig. 9) had shown signiﬁcant EndMT
after fractioned radiotherapy.
Tumour SMA+CD31+ vessels and coverage with SMA+NG2+
pericytes were correlated in >60% of tumour vessels in patients
who underwent surgery following neoadjuvant or combined
chemo-radiotherapy, compared to patients who did not receive
radiotherapy (Fig. 7a). In non-irradiated cancer tissues, 38% of
tumour cells were CD44v6+ (Fig. 7b). In contrast, 80% of residual
tumour cells were CD44v6+ in patients who underwent surgery
following neoadjuvant radiotherapy (Fig. 7b). Coincidently, in
irradiated cancer tissues, 62% of CD44v6+ CSCs were OPN+,
whereas 18% OPN+CD44v6+ CSCs were detected in non-
irradiated tissues (Fig. 7c). Additionally, in irradiated but not in
non-irradiated tissues, SDF-1+CD206+CD68+ M2 macrophages
were predominantly detected. SDF-1–iNOS+CD68+ M1 macro-
phages were hardly detected (<10%), although they were detected
more in irradiated than in non-irradiated tissues (Fig. 7d,
Supplementary Fig. 15). These data indicate that SDF-1+ M2
macrophage polarization might occur in irradiated human
tumours. Together, the occurrence of EndMT and subsequent
phenomena in human tissues support the clinical relevance of our
data.
Discussion
The ﬁndings of this study support a model for TRP53-regulated
radiation-induced EndMT and tumour vasculature (Fig. 7e).
EndMT induced abnormal recruitment of pericytes, including
SMA+, SMA+NG2+, and SMA+desmin+ cells, resulting in
abnormal vasculature after radiotherapy. Moreover, EndMT ECs
formed more tubules than non-EndMT ECs in vitro. While
mature tumour vessels can show substantial pericyte coverage
and abnormalities37, non-irradiated tumour vessels show less
pericyte coverage than EndMT-induced radioresistant vessels. We
suggest that radiation-speciﬁc vasculature development may stem
from tumour EndMT occurring shortly after radiotherapy, as
pericyte–EC communication is regulated by direct physical con-
tact and paracrine signalling21. Moreover, EndMT may give rise
to pericyte-like cells within tumours20 and be accompanied by
pericyte coverage29. Recent ﬁndings suggest that tumours
refractory to anti-vascular endothelial growth factor (anti-VEGF)
therapy or chemotherapy feature perivascular cells with sig-
niﬁcantly increased SMA expression20,38. Thus, radiotherapy with
anti-VEGF or anti-angiogenic therapy may be more efﬁcient
when combined with a strategy for inhibiting tumour EndMT.
Myeloid-lineage BMDCs are important in recurring irradiated
tumours7,8. In our study, during early tumour regrowth, BMDCs
recruited to EndMT vasculature after irradiation colocalized with
SMA+ cells, but not with ECs. We hypothesize that the recruited
BMDCs support SMA+ vessel maturation, as the origin of
tumour-vascular pericytes was traced to mesenchymal progenitor
cells or BMDCs21,39. A single, high dose (20 Gy) of non-curative
radiation used to examine vasculature development during the
initial-response, early-regrowth, and late-regrowth tumour phases
was insufﬁcient to eradicate all intratumour and peripheral
tumour vessels or angiogenic vessels surrounding the tumours. In
Fig. 4 Increased OPN expression during radiation-induced EndMT correlates with proliferating CD44v6+ cancer cells in hypoxic areas. a–c HUVECs were
transfected with siRNAs targeting TGFβR2, Trp53, or TGFβR2+ Trp53 for 48 h and irradiated (10 Gy). After 48 h in culture, total RNA was isolated for RNA-
seq and RT-qPCR analyses. a Heat map of RNA-seq analysis showing inhibition of radiation-induced EndMT and the mesenchymal phenotype in HUVECs
by Trp53 knockdown. b RT-qPCR analysis of EC-adhesion molecules, collagen, and ﬁbroblastic markers in HUVECs. c RT-qPCR analysis of OPN in HUVECs.
d Human soluble-receptor array analysis of conditioned medium from human pulmonary microvascular endothelial cells at 8 days after 5 Gy irradiation.
The cyan boxes mark the spots corresponding to OPN. e, f Immunoﬂuorescence detection of CD31 and OPN (e) or CD44v6, OPN, and CD31 (f) in KP
tumours from irradiated WT and EC-p53KO mice (23 dpi). Scale bar= 20 μm. g Quantiﬁcation of OPN+αSMA+CD31+ cells in the total CD31+ area (left)
and OPN+CD44v6+ cells in the total CD44v6+ area (right) (magniﬁcation, ×200; n > 5). Mouse strain designations are the same as in Figs 1 and 2. IR
irradiation (20 Gy). h, i KP tumour cells were cultured under normoxia, 1% O2 (mild hypoxia), or 0.5% O2 (severe hypoxia) and irradiated with or without
OPN. Data are representative of three independent experiments. h Immunoﬂuorescence detection of CD44v6 and Ki67 in KP tumour cells 11 days after
irradiation (left) and quantiﬁcation of CD44v6+Ki67+ cells in total CD44v6+ cells (right) (magniﬁcation, ×200; n > 5). Scale bar= 50 μm. i Flow-
cytometric analysis of EdU incorporation and CD44v6 expression in KP tumour cells 11 days after irradiation. For (b–d), the error bars indicate SD of three
independent experiments. For (g–i), the error bars indicate SEM; For (b, c), si-TGFβR2 + IR or si-Control + IR versus si-Control group, #p < 0.05, ##p <
0.01, ###p < 0.001, and ####p < 0.0001.si-p53 + IR or si-TGFβR2+si-p53 + IR versus si-Control + IR or si-TGFβR2 + IR group, respectively, *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, ns not signiﬁcant (d Student’s t-test, others: one-way ANOVA for multiple comparison)
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contrast, tumour EndMT was rarely detected in recurrent KP
tumours after radiotherapy with 2 times 25 Gy (Supplementary
Fig. 6). Therefore, angiogenesis may involve radioresistant
tumour ECs and normal tissue ECs surrounding the tumour,
which were unavoidably also irradiated during post-radiotherapy
tumour regrowth. Indeed, irradiated lung-tissue vessels show
signiﬁcant EndMT during radiation-induced lung ﬁbrosis25.
Thus, we suggest that modulating radiation-induced EndMT in
both normal and tumour tissues is a viable strategy for increasing
radiotherapy efﬁcacy.
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TRP53 is regarded a key regulator of radiation responses and
controlling cell survival and death; however, a reassessment of
targeting TRP53 as a paradigm for cancer therapy is in order40,41.
Our data revealed a novel role for TRP53 in the mesenchymal
transition of the tumour microenvironment, especially tumour
ECs, after radiotherapy.
TGFβ-related signalling potentially is also a key regulator of
EndMT. Unexpectedly, EC-Tgfbr2 knockdown enhanced
radiation-induced EndMT, with strongly increased SMAD2/3
phosphorylation, suggesting that TGFβR2 deletion may com-
pensatorily augment SMAD2/3 signalling via TGFβR1. Despite
the essential effects of the TGFβ pathway on cancer progression,
inhibiting TGFβ signalling in speciﬁc micro-environmental
niches has produced conﬂicting results42. For example, suppres-
sing TGFβ signalling in ﬁbroblasts promoted tumour
progression43,44, whereas stromal TGFβR2 expression decreased
as tumours progressed towards invasiveness45.
We found that EC-p53KO tumours regulated OPN, an
angiocrine factor acting on radioresistant CSCs, and EC recep-
tors, which in turn controlled TAMs, in the radioresistant tumour
microenvironment, supporting the observed role of tumour
angiocrine factors in the crosstalk between CSCs and tumour
vessels46,47. We suggest that OPN regulates tumour responses to
radiotherapy. OPN secreted during tumour EndMT strongly
accumulated on CD44v6+ CSC surfaces, implying that it acts as a
tumour angiocrine factor towards CD44v6+ cells. Moreover,
in vitro, non-proliferating CD44v6+ cells under severe hypoxia
after irradiation became activated after OPN treatment. Indeed,
dormant CD44v6+ CSCs were mainly detected in EC-p53KO
tumours showing severely hypoxic regions after radiotherapy and
CT26 cells prominently increased CD44v6 expression upon
irradiation. Although activated CSCs are considered important in
tumour relapse and escape, most CSCs are quiescent after radio-
and chemotherapy15,48. Moreover, it remains unknown how
awakened CSCs contribute to tumour relapse and escape. Based
on our observations, we cautiously hypothesize that dormant
(CD44v6+) CSCs may become awakened by angiocrine factors
(such as OPN) secreted during tumour EndMT-related revascu-
larization around hypoxic regions. Furthermore, we consider
CD44v6+ CSCs more important than other CSCs in radio-
therapy, as CD44v6+ populations were induced by radiation and
might be mainly responsible for post-radiotherapy tumour
regrowth and metastasis.
Irradiation seems to modulate tumour immunogenicity in
conventional radiotherapy and stereotactic ablative radio-
therapy3. High-dose radiation induces antigen production via
tumour cell death, tumour-speciﬁc immunity, and tumour-
vascular damage49. Radiation can attract immunosuppressive
cells to the tumour microenvironment17. TAM modulation is
considered important in cancer immunotherapy because of the
tumour-promoting effects of enhancing an immunosuppressive
microenvironment and tumour angiogenesis50,51. Klug et al.52
reported that low-dose irradiation stimulates immunostimulatory
macrophages, enabling cytotoxic T cells to inﬁltrate tumours, thus
boosting tumour immunity. In the current study, we discovered
that tumour vascularization via EndMT enhanced TAM polar-
ization toward M2-like macrophages and proliferation after
radiotherapy. M0 macrophages differentiated from BMDMs
prominently showed Arg1+ M2 polarization in coculture with
radiation-EndMT-derived tumour ECs. However, BMDMs
mainly polarized to the iNOS+M1 subtype during coculture with
ECs from EC-p53KO mice, in which radiation-induced EndMT
was inhibited. Accordingly, in vivo, at 1 dpi, tumours recruited
monocytes and F4/80+ macrophages. At 7 dpi, M2 macrophages
were mainly seen in WT tumours, while M1 macrophages were
predominantly observed in irradiated EC-p53KO tumours, indi-
cating that the tumour-vascular niche regulates TAM polarization
after radiotherapy. Detailed effects of radiation-induced EndMT
on other immune cells, including cytotoxic T and antigen-
presenting cells, remain to be explored.
High SDF-1/CXCL12 expression in tumours aids in the capture
of CXCR4-expressing monocytes36,50. Interestingly, strongly
SDF-1+ monocytes and subsequently SDF-1+CD206+ M2 mac-
rophages were recruited to KP tumours after radiotherapy. Fur-
thermore, EndMT tumour-derived ECs highly expressing CXCR4
induced M2 polarization and proliferation of SDF-1+ macro-
phages, which was inhibited by Trp53 silencing.
AMD3100 signiﬁcantly inhibited M2 SDF-1+ macrophage
polarization in coculture with irradiated tumour ECs. Relevant to
our ﬁndings with SDF-1+ macrophages, SDF-1 produced in
monocytes contributes to macrophage differentiation36. In
accordance with previous ﬁndings53, SDF-1+ tumour cells were
observed after radiation, but in this study, SDF-1 expression was
higher in monocytes than in tumour stromal cells; this dis-
crepancy may reﬂect a requirement for SDF-1 cleavage for cel-
lular activity, as monocytic SDF-1 was not strongly detected with
antibodies targeting the C terminus of SDF-1. We are currently
studying SDF-1 cleavage in relation to monocyte differentiation.
The effect of radiation-induced tumour-vascular damage on
TAM polarization, which was increased by EndMT, suggests that
high-dose radiation (~10 Gy) can evoke stronger tumour immune
responses than low-dose radiation, because it indirectly causes
tumour cell death via vascular damage11. In this study, targeting
EndMT more efﬁciently inhibited tumour regrowth after a single
high dose of radiation than after fractionated radiotherapy. In
fractionated radiotherapy, tumour EndMT was signiﬁcantly
Fig. 5 TRP53-regulated EndMT modulates the M1 and M2 populations of increased TAMs after radiotherapy. a RNA-seq data analysis of the samples
represented in Fig. 4a. Venn diagram depicting differentially expressed genes in irradiated HUVECs. Reverse-regulated genes (>1.2-fold) between TGFβR2
knockdown+IR and Trp53-knockdown (with and without TGFβR2 knockdown)+IR conditions (compared with IR alone) were selected (subgroup A). Only
matrisome- and surface-associated genes in subset A are shown in the heatmap generated by k-means clustering (subgroup B). b GeneMANIA network
analysis of subset B showing signiﬁcant enrichment for the GO term ‘leukocyte migration’. Red-ﬁlled circles represent genes upregulated in the Trp53
siRNA+IR group vs. the IR-alone group. Blue-ﬁlled circles represent genes upregulated in the TGFβR2 siRNA+IR group vs. the IR-alone group. The names of
leukocyte migration-related genes are indicated in red. c Immunoﬂuorescence detection of F4/80, CD31, and Arg1, or iNOS, CD31, and F4/80 in KP
tumours from WT and EC-p53KO mice, with or without irradiation (23 days after irradiation). Scale bar= 20 μm. d Quantiﬁcation of F4/80+Arg1+ and
F4/80+iNOS+ cells/ﬁeld (magniﬁcation, ×200) using immunoﬂuorescence images of KP tumours from WT, EC-p53KO, and TGFβR2KD mice, with or
without irradiation (23 days after irradiation). e Ratio of CD206+ in F4/80+ cells from WT and EC-p53KO tumours 7 days after irradiation, as determined
by ﬂow cytometry. f Immunoﬂuorescence staining of F4/80 and Arg1 in WT bone marrow-derived macrophages after coculture with KP tumour-derived
ECs fromWT and EC-p53KO mice for 48 h after irradiation. Scale bar= 50 μm (crop, 20 μm). Flow-cytometric analysis of CD206+, iNOS+, and EdU+ cells
among F4/80+ cells (magniﬁcation, ×200) is shown. For (d–f), error bars indicate SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns not
signiﬁcant (one-way ANOVA for multiple comparison). The mice were treated with a single 20 Gy dose of irradiation. Data are representative of three
independent experiments
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inhibited by EC-p53KO; however, CD44v6+ CSC proliferation
and tumour growth were not inhibited. Nevertheless, we cau-
tiously suggest that in fractionated radiotherapy, targeting
EndMT may enhance therapeutic efﬁcacy when combined with
inhibition of CSC proliferation.
In accordance with our ﬁndings in vivo, tumour EndMT was
prominently seen in lung cancer tissues of patients who received
irradiation, with large populations of OPN+CD44v6+ CSCs
and SDF-1+CD206+ macrophages, even though the patients
had received fractioned radiotherapy, indicating that
iN
O
S+
 
SD
F-
1+
 c
e
lls
in
 F
4/
80
+
 c
e
lls
 (%
)
CD
20
6+
 S
DF
-1
+
 c
e
lls
in
 F
4/
80
+
 c
e
lls
 (%
) *** ** * *** **
Br
dU
+
 S
DF
-1
+
 c
e
lls
in
 F
4/
80
+
 c
e
lls
 (%
)60
40
20
0
40
20
10
0
30
80
40
20
0
60
a
SDF1 / CD31 / DAPI
W
T,
 IR
 1
 d
ay
d
e
b
SD
F-
1 
/ F
4/
80
 / 
CD
20
6 
/ D
AP
I
IR
N
o 
IR
EC-p53KOWTcEC-p53KOWT
IR
N
o 
IR
CD
31
 / 
CX
CR
4 
/ D
AP
I
WT
f
g
F4/80 / SDF-1 / DAPI
M0
M1
M2
EC
-W
T
+
 C
oc
ul
tu
re
 W
ith
M
Φ
 
(48
 h
)
F4/80 / SDF-1 / CD206 / DAPI
EC
-p
53
KO
F4/80 / SDF-1 / iNOS / DAPI
h
R
el
at
iv
e 
R
N
A 
le
ve
l
si
-C
on
tro
l
si
-T
G
Fβ
R
2
+
 s
i-p
53
si
-C
on
tro
l
si
-p
53
si
-T
G
Fβ
R
2
IR
CXCR4
10
5
0
15
####
####
****
***
F4
/8
0 
/ S
DF
-1
 / 
CD
20
6 
/ D
AP
I
7 
D
ay
s 
po
st
 IR
N
o 
IR
EC-p53KOWT ****
WT EC-p53KO
WT EC-p53KO
40
20
0
60
80
CD
20
6+
 
ce
lls
 in
 S
DF
-1
+
F4
/8
0+
 c
e
lls
 (%
)
iN
O
S+
 
ce
lls
 in
 S
DF
-1
+
F4
/8
0+
 
ce
lls
 (%
) 
* 
40
20
0
60
%
 O
f p
os
itiv
e
 c
e
lls CD206
+
 F4/80+
**** ****
ns
IR, 7 DaysNo IR
40
20
0
60 SDF-1+ in CD206+ F4/80+
0
30
60
90
120
150
101 101 102 103 104
CD206–
M1
CD206+Co
un
ts
i
*
******
ns
CD
20
6+
 
SD
F-
1+
 c
e
lls
in
 F
4/
80
+
 c
e
lls
 (%
)
EC-p53KOWT
25
10
5
0
15
20
No IR
IR
IR+AMD3100
ECs:
+ Coculture with MΦ
(48 h)
F4/80 / SDF-1 / iNOS / DAPI
F4/80 / SDF-1 / CD206 / DAPI
LPS
IFN-γ
IL-4
IL-10
IRNo IR
CX
CR
4/
CD
31
40
20
0
WT
EC
-p5
3K
O
WT
EC
-p5
3K
O WT
EC
-p5
3K
O
WT
EC
-p5
3K
O
WT
EC
-p5
3K
O
WT
EC
-p5
3K
O
60 **** ****
No IR
No
 IR
IR
IR
IR+AMD3100
IR+
AM
D3
10
0
No
 IR IR
IR+
AM
D3
10
0
No
 IR IR
IR+
AM
D3
10
0
CD31 / SDF-1 / CD206 / DAPI
***
ns**
IRNo IR
N
o.
 S
DF
-1
+
ce
lls
 / 
HP
F
10
5
0
15
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07470-w ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5108 | DOI: 10.1038/s41467-018-07470-w |www.nature.com/naturecommunications 13
radiation-induced CD44v6+ tumour cells and SDF-1+ M2 mac-
rophages might be targeted for overcoming tumour
radioresistance.
In conclusion, this study provides evidence that targeting
radiation-induced EndMT is a new, promising strategy for
enhancing tumour radiosensitivity by inhibiting radiation-
induced abnormal tumour vasculature. Speciﬁcally, targeting
vascular EndMT may be effective in regulating radioresistant CSC
proliferation and maximizing the anti-tumour immunity of
radiotherapy.
Methods
Mice. All animal experiments were approved by the Institutional Animal Care and
Use Committee of the Korea Institute of Radiological & Medical Sciences and are
reported in accordance with the ARRIVE (Animal Research: Reporting of In Vivo
Experiments) guidelines54. Speciﬁc pathogen-free C57BL/6 Tie2-Cre, Trp53ﬂox/ﬂox,
Tgfbr2ﬂox/ﬂox, and LSL-KrasG12D mice were purchased from the Jackson Labora-
tory. Tie2-GFP mice were a kind gift from Dr. Gou Young Koh (Korea Advanced
Institute of Science and Technology). Male Tie2-Cre mice were crossed with female
Trp53ﬂox/ﬂox, Tgfbr2ﬂox/ﬂox, or Trp53ﬂox/ﬂoxTgfbr2ﬂox/ﬂox (generated by crossing
Trp53ﬂox/ﬂox and Tgfbr2ﬂox/ﬂox) mice to generate Tie2-Cre;Trp53ﬂox/+, Tie2-Cre;
Trp53ﬂox/ﬂox, Tie2-Cre;Tgfbr2ﬂox/+, Tie2-Cre;Trp53ﬂox/+Tgfbr2ﬂox/+, or Tie2-Cre;
Trp53ﬂox/ﬂoxTgfbr2ﬂox/+ mice. Tie2-Cre;Trp53+/+, Tie2-Cre;Tgfbr2+/+, Tie2-Cre;
Trp53+/+Tgfbr2+/+, or Tie2-Cre–/– littermates were used as controls. All animal
experimental data shown are representative of three independent experiments. All
experiments were conducted with 6–8-week-old mice. The mice had access to a
standard diet and water ad libitum. All mice were anaesthetized with a combina-
tion of anaesthetics before being killed. For in vivo proliferation assays, mice
received an intraperitoneal injection of 5-bromo-2-deoxyuridine (BrdU) (2 mg/
mouse) (Sigma-Aldrich) 4 h before tumour harvesting. BrdU+ cells were detected
using an anti-BrdU mouse monoclonal antibody (1:500, Sigma-Aldrich).
Human tissue specimens. The analysis of lung cancer patient tissues was
approved by the ethics committee of Severance Hospital, Yonsei University
(Korea). In addition, a lung cancer tissue with information related to radiotherapy
was purchased from Origene (cat. no. CT565899). Clinicopathological character-
istics of 10 patients (Severance Hospital patient tissues, n= 7; Origene tissues, n=
3) who received radiotherapy and 10 patients (Origene tissues, n= 10) who did not
receive radiotherapy are shown in Supplementary Table 1.
Bone marrow transplantation. CT26 cells (5 × 105) were injected subcutaneously
into the right thigh of 8-week-old male BALB/c mice. When the tumour volume
reached 150–200 mm3, tumours or whole mice were irradiated with a sublethal
dose (8 Gy). Bone marrow cells were harvested from the tibias and femurs of male
BALB/c donor mice and were ﬂuorescently labelled with CM-Dil dye (1: 500,
Molecular Probes), per the manufacturer’s instructions. CM-Dil-labelled cells (2 ×
107) were suspended in 200 μl of Opti-MEM (Gibco) and intravenously injected
into whole body-irradiated mice at 6 hpi. Tumours from control and transplanted
mice were harvested at 7 dpi. KP tumour-bearing recipient mice were sub-lethally
irradiated (9 Gy), and 9 h after irradiation, they received Tie2-GFP mouse-derived
bone marrow cells (1 × 107 cells) intravenously and were allowed to recover for
3 weeks.
Histology and immunohistochemistry. Tumour tissues were covered with opti-
mal cutting temperature (OCT) compound (Sakura Finetek; VWR, IL, USA) and
snap-frozen on dry ice or ﬁxed in 10% (v/v) neutral-buffered formalin, embedded
in parafﬁn, and sectioned. The sections were deparafﬁnized and stained as pre-
viously described25. The staining procedure for OCT sections was the same as that
for parafﬁn-embedded sections, except that antigen removal was omitted. At least
ﬁve images per section were acquired for quantiﬁcation, and positively stained
areas were evaluated with ImageJ software (http://imagej.net/).
Tumour EC and macrophage coculture. For coculture experiments, tumour ECs
were plated in 6-well plates, with or without radiation. BMDMs (1.2 × 105), dif-
ferentiated by treatment with murine M-CSF every other day for 7 days, were
placed on the tumour ECs. The cocultures were harvested at 48 h. Tumour ECs and
BMDMs cultured alone were used as controls.
AMD3100 treatment. KP tumour cells (2 × 105) were injected subcutaneously
into the right thighs of C57BL/6 mice. When the tumours reached 150–200 mm3, a
single dose of radiation (20 Gy) was delivered using the X-RAD 320 platform
(Precision X-ray). AMD3100 (Sigma-Aldrich) was dissolved in distilled water,
diluted in phosphate-buffered saline, and administrated daily intraperitoneally (5
mg/kg) for 7 days.
Syngeneic tumour models. CT26 cells (5 × 105) were injected subcutaneously into
the right thighs of male BALB/c mice. KP tumour cells (2 × 105) were injected
subcutaneously into the right thighs of Tie2-Cre;Trp53ﬂox/+, Tie2-Cre;Trp53ﬂox/ﬂox,
Tie2-Cre;Tgfbr2ﬂox/+, Tie2-Cre;Trp53ﬂox/+Tgfbr2ﬂox/+, Tie2-Cre;Trp53ﬂox/
ﬂoxTgfbr2ﬂox/+, Tie2-Cre;R26RtdTomato;Trp53ﬂox/ﬂox, and VE-cadherin-CreERT2;
Trp53ﬂox/ﬂox mice and control littermates. Tumour volumes were determined
according to the formula (L ×W ×H)/2, using the calliper-measured tumour length
(L), width (W), and height (H). When tumour volumes reached 150–200 mm3,
radiation was delivered, using the X-RAD 320 platform (Precision X-ray). For OPN
blocking experiments, mice were intraperitoneally injected with an anti-mouse
OPN neutralizing antibody (20 μg/injection; R&D systems) four times, every
2 days.
Mouse experiments. To visualize functional vasculature, mice were intravenously
injected with Hoechst 33342 (20 mg/kg; Sigma) 1 min prior to killing. For hypoxia
assessment, pimonidazole (60 mg/kg) was administered intraperitoneally. After 45
min, the mice were killed and tumours were harvested, ﬁxed, and immunostained
using the Hypoxyprobe Plus Kit (Hypoxyprobe) per the manufacturer’s instruc-
tions. To evaluate tumour metastasis, metastatic nodules on lung surfaces observed
by the naked eye were counted. To visualize tumour vessel leakage, mice were
intravenously injected with ﬂuorescein isothiocyanate–dextran (70 kDa, 40 mg/kg;
Sigma) 5 min before killing.
Flow-cytometric analysis. At day 7, tumour samples were harvested and digested
into single-cell suspensions. Cells were stained with macrophage-speciﬁc anti-
bodies. The cells were ﬁxed and permeabilized using the Cytoﬁx/Cytoperm Kit (BD
Biosciences) and stained with an anti-SDF1 antibody. Then, the cells were analysed
on a FACSCalibur ﬂow cytometer (Becton Dickinson, San Jose, CA). Gating
strategies for ﬂow cytometry analysis are shown in Supplementary Figure 16.
Fig. 6 EC-Trp53 deletion attenuates endothelial CXCR4 expression and M2 polarization of SDF-1+ TAMs after a single 20-Gy irradiation. a RT-qPCR
analysis of CXCR4 in HUVECs 48 h post 10 Gy irradiation. HUVECs were transfected with TGFβR2, Trp53, or TGFβR2+Trp53 siRNAs 2 days before
irradiation. si-TGFβR2 + IR or si-Control + IR versus si-Control group, ####p < 0.0001.si-p53 + IR or si-TGFβR2+si-p53 + IR versus si-Control + IR or si-
TGFβR2 + IR group, respectively, ***p < 0.001 and ****p < 0.0001. b Immunoﬂuorescence of CD31 and CXCR4 in KP tumours. CXCR4+CD31+ cell
quantitation (magniﬁcation, ×200) is shown. Scale bar= 20 μm. c Immunoﬂuorescence of SDF-1, F4/80, and CD206 in KP tumours, with or without
irradiation (23 dpi). Quantiﬁcation of SDF-1+ cells (magniﬁcation, ×200) is shown. Scale bar= 50 μm. d Immunoﬂuorescence of SDF-1 and CD31 in KP
tumours from WT mice 1 dpi. Scale bar= 10 μm e Immunoﬂuorescence of F4/80, SDF-1, and CD206 in KP tumours 7 dpi. Scale bar= 20 μm (crop, 5 μm).
Quantiﬁcation of CD206+ and iNOS+ cells among SDF-1+F4/80+ cells (magniﬁcation, ×200). f Flow-cytometric analysis of SDF-1+ cells in CD206+F4/
80+ cells of KP tumours at 7 dpi. g Immunoﬂuorescence of F4/80, SDF-1, and CD206 in BMDMs after a 48-h coculture with KP tumour-derived ECs. As
controls, BMDMs from WT mice were polarized to M1 or M2 macrophages by treatment with LPS (100 ng/ml) plus IFNγ (20 ng/ml), or IL-10 (20 ng/ml)
plus IL-4 (20 ng/ml), respectively, for 48 h. Scale bar= 20 μm. h Immunoﬂuorescence of CD31, SDF-1, and CD206 in KP tumours from WT mice at 7 dpi,
with or without AMD3100 treatment. BrdU was used for in vivo proliferation assays. CD206+SDF-1+ TAMs, iNOS+SDF-1+ TAMs, and non-differentiated
SDF-1+ monocytes are marked with yellow, green, and open arrows, respectively. Quantiﬁcation of CD206+SDF-1+ and iNOS+SDF-1+ cells among F4/80
+ cells (magniﬁcation, ×200) and ﬂow-cytometric analysis of BrdU+SDF-1+ cells in F4/80+ cells. Scale bar= 10 μm. i Flow-cytometric analysis of SDF-1
+CD206+ cells in F4/80+ cells of WT BMDMs after coculture with KP tumour-derived ECs from WT and EC-p53KO mice for 48 hpi, with or without
AMD3100 treatment. Error bars indicate SD (a) or SEM (c, e, f, h, i); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns not signiﬁcant (one-way
ANOVA). Data are representative of three independent experiments
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Flow-cytometric analysis of 5-ethynyl-2′-deoxyuridine (EdU) incorporation.
For in vitro proliferation assays, KP cells were irradiated with gamma rays from
a [137Cs] source (Atomic Energy of Canada) at 3.81 Gy/min. To establish
hypoxia, cells were incubated in a Forma 1025/1029 Anaerobic Chamber
(Thermo Fisher Scientiﬁc) ﬂushed with 0.5% or 1% O2 for severe or mild
hypoxia, respectively. Cells were incubated with 10 μM EdU for 2 h, trypsinized,
and surface-stained with an anti-CD44v6 antibody (Novus Biologicals, USA).
The cells were labelled using the Click-iT Alexa Fluor 488 Assay Kit (C10420;
Thermo Fisher Scientiﬁc) and analysed on a FACSCalibur (Becton Dickinson,
San Jose, CA).
Generation of BMDMs. Femurs and tibiae were collected from adult male C57BL/
6 mice, and the bones were ﬂushed using syringes ﬁlled with RPMI-1640 medium
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(WELGENE, Gyeongsan, South Korea) supplemented with 1% penicillin/strepto-
mycin and 10% foetal bovine serum (FBS). Red blood cells were lysed using lysis
buffer (catalogue number R7757; Sigma). Bone marrow cells were seeded onto 100
mm culture dishes and incubated at 37 °C under 5% CO2. Non-adherent cells were
removed at day 3. The attached cells were cultured with fresh medium containing
murine M-CSF every other day for 7 days. On day 7, M1 macrophages were
characterized by the expression of inducible nitric oxide synthase (iNOS) and
induced with LPS (100 ng/ml) or IFN-γ (20 ng/ml), whereas M2 macrophages were
characterized by the expression of CD206 and induced with IL-4 (20 ng/ml) or IL-
10 (20 ng/ml).
Immunoblotting and immunohistochemistry. Staining for immunohistochem-
istry, immunoﬂuorescence, and ﬂow cytometry was carried out using primary
antibodies against CD31 (Immunoﬂuorescence 1:200; R&D Systems; #AF3628,
Immunoblotting 1:1000; Santa Cruz; #sc-1506) and αSMA (1:1000; Sigma-Aldrich;
#A5228); vimentin (1:10,000; Santa Cruz; #sc-6260), phospho-SMAD2/3 (1:1000,
Cell Signaling; #8828), phospho-SMAD1/5 (1:1000, Cell Signaling; #9516), p53
(1:1000; Santa Cruz; #sc-126), CD44 (1:200; Santa Cruz; #sc-7297), GFP (1:100;
Santa Cruz; #sc-9996), SMAD2/3 (1:1000, Cell Signaling; #3102), TGFβR1 (1:1000;
Santa Cruz; #sc-339), TGFβR2 (1:1000; Santa Cruz; #sc-17792), OPN (1:100; Santa
Cruz; #sc-21742), iNOS (1:100; Santa Cruz; #sc-21860), Nanog (1:200; Santa Cruz;
#sc-134218), Oct4 (1:200; Santa Cruz; #sc-5279), Sox2 (1:200; Santa Cruz; #sc-
20088), and CD4 (1:200; Santa Cruz; #sc-52385); EpCAM (1:200; Biorbyt;
#orb10618); CD44v6 (1:500; Novus Biologicals; #NEB100-64818) and arginase 1
(1:2000; Novus Biologicals; #NBP1-32731); NG2 (1:500; Millipore; #AB5320); Ki67
(1:200; Acris; #DRM004); RasG12D (1:100; New East Biosciences; #26036); β-
Catenin (1:200; BD; #610153); desmin (1:200; Abcam; #ab8592), ALDH1 (1:200;
Abcam; #ab52492), γH2AX (1:200; Abcam; #ab2893), F4/80 (1:200; Abcam;
#ab6640), CD206 (1:200; Abcam; #ab8918), SDF-1 (1:200; Abcam; #ab18919),
MHCII ((1:200; Abcam; #ab25333), CD8 (1:200; Abcam; #ab22378), Granzyme B
(1:200; Abcam; #ab4059), and Foxp3 (1:200; Abcam; #ab54501). Scanned images of
western blots are shown in Supplementary Figure 17. Hoechst 33342 staining was
applied directly to frozen OCT sections. Collagen deposition was assessed using
Masson’s trichrome stain (Sigma-Aldrich). For TUNEL (terminal deoxynucleotidyl
transferase dUTP nick end labelling) staining, the DeadEnd Fluorometric TUNEL
System (Promega) was used. To visualize actin stress ﬁbres, cells were stained with
Alexa Fluor 488-conjugated phalloidin (1:40; Invitrogen), which speciﬁcally binds
polymerized F-actin. At least ﬁve images per section were acquired for quantiﬁ-
cation, and positively stained areas were evaluated with ImageJ software (http://
imagej.net/).
RNAscope in situ hybridization and immunoﬂuorescence staining. Frozen
OCT sections were used for in situ hybridization assays. Trp53 mRNA was stained
using a Trp53-speciﬁc probe (Advanced Cell Diagnostics, #513001-C3;
NM_011640.3, region 159–1238) and the RNAscope Fluorescent Multiplex
Reagent Kit (Advanced Cell Diagnostics, #320850), according to the manu-
facturer’s instruction. Thereafter, sections were blocked with normal horse serum
for 30 min at room temperature and incubated with a primary antibody overnight
at 4 °C. Trp53 mRNA transcripts and VE-cadherin were visualized with TSA Plus
ﬂuorescein (PerkinElmer) and an Alexa Fluor 647-labelled secondary antibody
(Invitrogen), respectively.
Cell culture and treatments. HUVECs, human pulmonary microvascular endo-
thelial cells (HPMECs), and human pericytes were obtained from PromoCell
(Sungwoo Life Science, Uijeongbu, South Korea) and were cultured in Endothelial
Cell Growth Medium 2, Endothelial Cell Growth Medium MV2, and Pericyte
Growth Medium, respectively (Promocell) under 5% CO2. HUVECs, HPMECs,
and pericytes were used within nine passages. CT26 mouse colon carcinoma cells
were a kind gift from Dr. Sam S. Yoon. The cells were cultivated in RPMI-1640
(WELGENE) supplemented with 10% FBS. CT26 cells stably expressing enhanced
green ﬂuorescent protein (EGFP) were established by transduction with a lentiviral
vector expressing EGFP under the control of the cytomegalovirus promoter
(Invitrogen), according to the manufacturer’s protocol. KP cells were isolated from
lung adenocarcinoma samples of LSL-KrasG12D;Trp53ﬂox/ﬂox mice30. Primary lung
tumours were digested for 1 h at 37 °C with 1 mg/ml collagenase I (Gibco) in
phosphate-buffered saline and cultured in Dulbecco’s modiﬁed Eagle’s medium
(WELGENE) supplemented with 10% FBS. KP cells at passages 3–6 were used for
transplantation. For silencing experiments, cells were transfected with siRNAs
targeting Trp53 and Tgfbr2 as well as control siRNA (Santa Cruz Biotechnology)
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s recom-
mendations. Cells were irradiated with gamma rays from a [137Cs] source (Atomic
Energy of Canada) at 3.81 Gy/min. For the analysis of secreted proteins, condi-
tioned media were collected between days 6 and 7 of HPMEC culture after irra-
diation and assayed using Proteome Proﬁler Human Soluble Receptor Array,
Hematopoietic Kit (R&D Systems, ARY001), according to the manufacturer’s
instructions. For the analysis of cellular proteins, immunocytochemistry was per-
formed as previously described26. OPN released by HUVECs into the culture
medium was measured using a human OPN Quantikine ELISA Kit (R&D Sys-
tems), following the manufacturer’s instructions.
RNA-seq analysis. Total RNA was isolated from HUVECs, and RNA quality was
assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA-seq
libraries were constructed using the SENSE mRNA-Seq Library Prep Kit (Lexogen),
according to the manufacturer’s instructions, and were sequenced as 100 bp paired-
end runs on the HiSeq 2000 platform (Illumina). RNA-seq reads were mapped to
UCSC hp19 using TopHat software55. Fragments-per-kilobase-of-transcript values
were calculated with Cufﬂinks55. Genes with a maximal log2-transformed read
count <5 across samples were excluded from the analysis. To identify differentially
expressed genes, we compared the direction of fold changes (>1.2) against irra-
diation (IR) alone. Reverse-regulated genes (>1.2-fold) between TGFBR2 knock-
down+IR and p53 knockdown (with and without TGFBR2 knockdown)+IR
compared with IR alone were selected. To analyse angiocrine factors and pheno-
typic changes in endothelial cells, matrisome gene lists and surfactome gene lists
were used. The matrisome comprises core matrisome-related proteins, including
extracellular matrix (ECM) glycoproteins, collagens, and proteoglycans, as well as
ECM-associated proteins, including ECM-afﬁliated proteins, ECM regulators, and
secreted factors56. The surfactome represents proteins at the plasma membrane,
including G protein-coupled receptors, receptor tyrosine kinases, and integrins57.
Among the differentially expressed genes, matrisome and surfactome genes were
displayed in R using the ComplexHeatmap package58 and were used as input for
the GeneMANIA 3.4.1 plugin59 within Cytoscape 3.4.060 for functional enrichment
analysis. RNA-seq data generated in this study are available on Gene Expression
Omnibus (GEO, accession number GSE118538)
RT-qPCR analysis. RNA was isolated using TRI reagent (MRC, Cincinnati, OH,
USA), and 1 μg of RNA was used to synthesize complementary DNA with an
Omniscript RT Kit (Qiagen, Hilden, Germany). PCR was conducted in triplicate on
the CFX96 TM Real-Time system (Bio-Rad, Hercules, CA, USA), using qPCR
SYBR Green master mix (Invitrogen). For each sample, target gene expression was
normalized against the geometric mean of the reference gene GAPDH. Primers are
listed in Supplementary Table 3.
Fig. 7 EndMT-related phenomena in human lung cancer tissues from patients treated with or without radiotherapy. Sections from non-irradiated (n= 10)
and irradiated (n= 10) lung cancer tissues were analysed (a–d). a Immunoﬂuorescence detection of CD31, αSMA, and NG2 in irradiated tissues.
Quantiﬁcation of αSMA+CD31+ among the total CD31+ cells or vessels with αSMA+NG2+ pericytes (magniﬁcation, ×100). Scale bar= 20 μm.
b Immunoﬂuorescence detection of CD44v6 expression in non-irradiated and irradiated tissues. Quantiﬁcation of the CD44v6 intensity and CD44v6+
area/ﬁeld (magniﬁcation, ×100) is shown. Scale bar= 50 μm. c Immunoﬂuorescence detection of CD44v6 and OPN expression in irradiated tissues.
Quantiﬁcation of CD44v6+OPN+ cells in the total CD44v6+ area (magniﬁcation, ×100) is shown. Scale bar= 20 μm. d Immunoﬂuorescence detection of
CD206, SDF-1, and CD68 in irradiated human lung cancer tissues. Scale bar= 20 μm (crop, 10 μm). Quantiﬁcation of SDF-1+CD206+CD68+ cells in SDF-
1–iNOS+CD68+ cells total CD68+ cells (magniﬁcation, ×100) is shown. a–d Error bars indicate SEM; **p < 0.01, ***p < 0.001, ****p < 0.0001 (Student’s t-
test). e Model for TRP53-regulated irradiation-induced EndMT and tumour vasculature. Radiation-induced tumour EndMT causes aggressive tumour-
vasculature growth, recruiting abnormal αSMA+ or NG2+αSMA+ pericytes. Firstly, vascular ECs occur in EndMT secreted OPN, which trigger the
proliferation of radioresistant dormant hypoxic CD44v6+ CSCs with metastatic potential. Secondly, EndMT cells overexpressing CXCR4 serve as a
reservoir for M2 macrophages polarized from SDF-1-positive monocytic cells. These phenomena synergistically affect aggressive tumour regrowth after
radiotherapy. However, endothelial TRP53 deletion inhibits radiation-reduced EndMT and aberrant tumour vasculature. Subsequently, inhibited OPN
secretion and CXCR4 expression can synergistically inhibit tumour regrowth after radiotherapy. Our ﬁndings suggest that targeting radiation-tumour
EndMT, as the marker of radioresistant tumour, may enhance radiotherapy efﬁcacy both by inhibiting the reactivation of dormant CSCs and by promoting
radiation-antitumour immune responses, representing a potentially viable, new therapy
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Statistical analyses. Student’s t-test (Figs. 2a–c, 3b, lower, 3f, right, 3g, left, 4d, 5f,
right, 6e, 7a–d) and analysis of one-way analysis of variance (ANOVA) for multiple
comparison (for all others) in GraphPad Prism version 5.0 were used to compare
experimental groups. A p value < 0.05 was regarded signiﬁcant. Experimenters were
blinded to group assignments and outcome assessments.
Data availability
The RNA-seq data were deposited in Gene Expression Omnibus (GEO) with
accession number GSE118538. All other relevant data are available from the cor-
responding author upon reasonable request.
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